OPKO Biologics will host a symposium at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology and will present the complete 12-month pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO’s weekly long-acting growth hormone (hGH-CTP) in naïve growth hormone deficient children. The 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology is […]
Author Archive for: opkomanager
This author has yet to write their bio.Meanwhile lets just say that we are proud opkomanager contributed a whooping 7 entries.
Entries by opkomanager
OPKO Biologics presented clinical data from its completed 12-month hGH-CTP Phase 2 pediatric growth hormone deficiency clinical study in two oral presentations at the 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) on October 3, 2015, in Barcelona, Spain. The presentations included pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO’s hGH-CTP in […]
OPKO Health, Inc. has completed enrollment in the single pivotal Phase 3 trial of its long acting human growth hormone (hGH-CTP) in growth hormone deficient (GHD) adults. The trial is designed to evaluate the safety and efficacy of hGH-CTP with a primary endpoint of superiority compared to placebo in decreasing fat mass in adults with […]
New Preclinical Data further demonstrate the safety and efficacy of MOD-5014 (FVIIa -CTP) for both Intravenous and Subcutaneous Administration OPKO Health, Inc. presented new data on its long-acting clotting Factor VIIa-CTP (MOD-5014) at the International Society on Thrombosis and Haemostasis Congress (ISTH 2015) held June 20-25, 2015 in Toronto, Ontario, Canada. OPKO’s Factor VIIa-CTP is […]
OPKO Health, Inc. announced the presentation of two posters at the 97th Annual Meeting of the Endocrine Society (ENDO 2015) on March 5th, 2015 in San Diego, California, that included twelve months data from OPKO’s advanced phase 2 trial for its long acting human growth hormone hGH-CTP in growth hormone deficient pediatric subjects. The presented data […]
OPKO Health, Inc. announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO’s long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or […]
OPKO Health, Inc. and Pfizer Inc. announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows termination of the waiting period under the Hart-Scott Rodino Act.